Tazemetostat with Rifabutin Interaction Details


Brand Names Associated with Tazemetostat

  • Tazemetostat
  • Tazverik®

Brand Names Associated with Rifabutin

  • Mycobutin®
  • Rifabutin
  • Talicia (as a combination product containing Amoxicillin, Omeprazole, Rifabutin)

Medical Content Editor
Last updated Dec 19, 2023


Curious for more information about this interaction?

Ask our pharmacists directly!

Reach out to us

Interaction Effect

Decreased tazemetostat exposure


Interaction Summary

Concomitant use of tazemetostat with a strong or moderate CYP3A inducer may decreases tazemetostat plasma concentrations, which may decrease the efficacy of tazemetostat. Concomitant use should be avoided.


Severity

Major


Onset

Unspecified


Evidence

Theoretical


How To Manage Interaction

Concomitant use of tazemetostat with a strong or moderate CYP3A inducer may decreases tazemetostat plasma concentrations, which may decrease the efficacy of tazemetostat. Concomitant use should be avoided.


Mechanism Of Interaction

Induction of CYP3A-mediated tazemetostat metabolism

Tazemetostat Overview

  • Tazemetostat is used to treat epithelioid sarcoma (a rare, slow-growing soft tissue cancer) in adults and children 16 years of age and older that has spread to nearby tissues or to other parts of the body and cannot be treated successfully with surgery. It is also used to treat certain types of follicular lymphoma (FL; a type of cancer that begins in the white blood cells) in adults whose cancer that has returned or did not respond to at least two other medications. Tazemetostat is also used to treat follicular lymphoma in adults that has returned or did not respond to treatment when no other treatment options are available. Tazemetostat is in a class of medications called EZH2 inhibitors. It helps to stop the spread of cancer cells.

See More information Regarding Tazemetostat

Rifabutin Overview

  • Rifabutin helps to prevent or slow the spread of Mycobacterium avium complex disease (MAC; a bacterial infection that may cause serious symptoms) in patients with human immunodeficiency virus (HIV) infection. It is also used in combination with other medications to eliminate H. pylori, a bacteria that causes ulcers. Rifabutin is in a class of medications called antimycobacterials. It works by killing the bacteria that cause infection.

  • Antibiotics such as rifabutin will not work for colds, flu, or other viral infections. Using antibiotics when they are not needed increases your risk of getting an infection later that resists antibiotic treatment.

See More information Regarding Rifabutin

Return To Our Drug Interaction Homepage


Feedback, Question Or Comment About This Information?

Ask , our medical editor, directly! He's always more than happy to assist.


Definitions

Severity Categories

Contraindicated

These drugs, generally, should not be used together simultaneously due to the high risk of severe adverse effects. Combining these medications can lead to dangerous health outcomes and should be strictly avoided unless otherwise instructed by your provider.


Major

This interaction could result in very serious and potentially life-threatening consequences. If you are taking this drug combination, it is very important to be under close medical supervision to minimize severe side effects and ensure your safety. It may be necessary to change a medication or dosage to prevent harm.


Moderate

This interaction has the potential to worsen your medical condition or alter the effectiveness of your treatment. It's important that you are monitored closely and you potentially may need to make adjustments in your treatment plan or drug dosage to maintain optimal health.


Minor

While this interaction is unlikely to cause significant problems, it could intensify side effects or reduce the effectiveness of one or both medications. Monitoring for changes in symptoms and your condition is recommended, and adjustments may be made if needed to manage any increased or more pronounced side effects.


Onset

Rapid: Onset of drug interaction typically occurs within 24 hours of co-administration.

Delayed: Onset of drug interaction typically occurs more than 24 hours after co-administration.


Evidence

Level of documentation of the interaction.

Established: The interaction is documented and substantiated in peer-reviewed medical literature.

Theoretical: This interaction is not fully supported by current medical evidence or well-documented sources, but it is based on known drug mechanisms, drug effects, and other relevant information.


How To Manage The Interaction

Provides a detailed discussion on how patients and clinicians can approach the identified drug interaction as well as offers guidance on what to expect and strategies to potentially mitigate the effects of the interaction. This may include recommendations on adjusting medication dosages, altering the timing of drug administration, or closely monitoring for specific symptoms.

It's important to note that all medical situations are unique, and management approaches should be tailored to individual circumstances. Patients should always consult their healthcare provider for personalized advice and guidance on managing drug interactions effectively.


Mechanism Of Interaction

The theorized or clinically determined reason (i.e., mechanism) why the drug-drug interaction occurs.


Disclaimer: The information provided on this page is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional regarding your specific circumstances and medical conditions.

Where Does Our Information Come From?

Information for our drug interactions is compiled from several drug compendia, including:

The prescribing information for each drug, as published on DailyMED, is also used. 

Individual drug-drug interaction detail pages contain references specific to that interaction. You can click on the reference number within brackets '[]' to see what reference was utilized.

The information posted is fact-checked by HelloPharmacist clinicians and reviewed quarterly.